Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

Overview of attention for article published in Journal of Clinical Immunology, April 2012

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#46 of 1,862)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 2 news outlets
twitter: 2 X users

patent: 102 patents
wikipedia: 2 Wikipedia pages

Citations

dimensions_citation: 397 Dimensions

Readers on

mendeley: 363 Mendeley

Summary News X Patents Wikipedia Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

Combination Therapies: Opportunities for Improved CAR-T Cell Therapy?

Labiotech.eu, 03 Nov 2021

Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed.

Cellular therapies for solid cancer: clinical experience, challenges and future revolution

BioInsights, 02 Jul 2020

Overview Immunotherapy has now emerged as the next frontier in cancer treatment.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.